MedTrace Logo

Characterization of Skin Changes From the Use of Moisturizers in Participants With Cancer Experiencing Dermatological Adverse Events

NCT07767448 · Status: NOT_YET_RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 50

Last updated 2026-08-21

No results posted yet for this study

Summary

The goal of this clinical trial is to evaluate whether cosmeceutical topical moisturizers can help with skin dryness in participants with cancer experiencing a dermatological adverse event from cancer therapies. The main question it aims to answer is:

Does cosmeceutical topical moisturizers help with skin dryness?

Participants will:

* Visit the clinic for a baseline visit to complete skin evaluation and tests.
* Apply cosmeceutical topical moisturizers daily from baseline up until the follow-up visit.
* Visit the clinic for a follow-up visit (approximately 2-4 weeks from baseline) for a repeat skin evaluation and tests.

Conditions

Interventions

OTHER

La Roche Posay Lipikar Wash Atopy-Prone Plus (AP+) Moisturizing Face and Body Wash

Moisturizer wash applied once in the morning and once in the evening.

OTHER

La Roche Posay Lipikar AP+ Triple Repair Moisturizing Cream

Moisturizer applied once in the morning and once in the evening.

OTHER

La Roche Posay Cicaplast balm Panthenol/Vitamin B5 (B5+)

Balm applied once in the morning and once in the evening.

Sponsors & Collaborators

Principal Investigators

  • Lisa Zaba, MD, PhD · Stanford University

Study Design

Allocation
NA
Purpose
SUPPORTIVE_CARE
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-08-31
Primary Completion
2028-09-30
Completion
2029-02-28

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07767448 on ClinicalTrials.gov